CAP37 Peptide Compounds for Scalable Antibacterial Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Gram-negative bacterial infections lack effective new antibiotics, with limited options for therapies that can circumvent antibiotic resistance, and existing peptides like CAP37 (20-44) face challenges in scalability, purity, and maintaining activity, necessitating the development of novel peptide compounds with enhanced antibacterial and wound-healing properties.
Innovation Solution
Development of peptide compounds derived from CAP37, specifically modified sequences like BCC02-5RMP, 95-122, and 120-146, which incorporate additional arginine residues and solubilizing moieties such as AEEP, to enhance solubility, purity, and antibacterial activity against Gram-negative bacteria, including resistant strains, while also promoting wound healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If the native CAP37 peptide sequence (20-44) is used, then antibacterial activity is achieved, but scalability and purity >90% cannot be attained
Solution Approach 1:
The patent modifies the native CAP37 peptide sequence by substituting cysteine residues with serine residues (C26S and C42S mutations). This parameter change in the amino acid sequence eliminates disulfide bond formation requirements, enabling scalable chemical synthesis and achieving purity >90% while maintaining antibacterial activity against Gram-negative bacteria.
2Reliability
If novel peptide compounds with enhanced properties are developed, then solubility and purity improve, but complexity of peptide design and synthesis increases
Solution Approach 1:
The patent introduces solubilizing modifications to the peptide sequence, including substitution of hydrophobic residues and addition of charged amino acids. These parameter changes in the peptide's chemical properties enhance solubility in aqueous solutions, enabling reliable production and formulation while the modular design approach keeps synthesis complexity manageable.
Data Source
Figure 1~2
Figure 3~5
Figure 4A~4D
AI summary
Peptide compounds based on the CAP37 protein are disclosed, along with methods for treating various infections, wounds, and conditions, and methods of promoting healing and acceptance of grafts, using compositions containing these peptide compounds.